David P. Nichols

Also affiliated with Seattle Children's Hospital

MedicineHealth Professions

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 23 papers. Top paper: “Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist”.

Pharmacologic improvement of CFTR function rapidly decreases sputum pathogen density, but lung infections generally persist

Journal of Clinical Investigation(2023)10.1172/jci167957

N/A

4.7DataRank · unranked

210 citations

Sarah J. Morgan, M. Skalland, Anh T. Vo, Jill M. Van Dalfsen, Sachinkumar B. Singh +9 more

Elexacaftor/tezacaftor/ivacaftor and gastrointestinal outcomes in cystic fibrosis: Report of promise-GI

Journal of Cystic Fibrosis(2022)10.1016/j.jcf.2022.10.003

N/A

4.1DataRank · unranked

125 citations

Phuong T. Vu, M. Skalland, Lucas R. Hoffman, Christopher E. Pope, Daniel Gelfond +16 more

Discontinuation versus continuation of hypertonic saline or dornase alfa in modulator treated people with cystic fibrosis (SIMPLIFY): results from two parallel, multicentre, open-label, randomised, controlled, non-inferiority trials

The Lancet Respiratory Medicine(2022)10.1016/s2213-2600(22)00434-9

N/A

3.9DataRank · unranked

127 citations

Félix Ratjen, Renee Russell, Scott H. Donaldson, Kristin A. Riekert, Gregory S. Sawicki +91 more

Effect of elexacaftor/tezacaftor/ivacaftor on mucus and mucociliary clearance in cystic fibrosis

Journal of Cystic Fibrosis(2023)10.1016/j.jcf.2023.10.010

N/A

1.0DataRank · unranked

31 citations

Timothy E. Corcoran, Joseph M. Pilewski, Peter J. Mogayzel, Beth L. Laube, Evan R. Boitet +10 more

Building global development strategies for cf therapeutics during a transitional cftr modulator era

Journal of Cystic Fibrosis(2020)10.1016/j.jcf.2020.05.011

N/A

0.520DataRank · unranked

31 citations

Silke van Koningsbruggen‐Rietschel, David P. Nichols, Donald R. VanDevanter, Jane C. Davies, T. Lee +20 more

Prospective evaluation of nontuberculous mycobacteria disease in cystic fibrosis: The design of the PREDICT study

Journal of Cystic Fibrosis(2023)10.1016/j.jcf.2023.08.007

N/A

0.488DataRank · unranked

6 citations

Silvia M. Caceres, Katie R. Poch, N. Rysavy, Valerie K. Lovell, Emily Armantrout +14 more

The effect of discontinuing hypertonic saline or dornase alfa on mucociliary clearance in elexacaftor/tezacaftor/ivacaftor treated people with cystic fibrosis: The SIMPLIFY-MCC Study

Journal of Cystic Fibrosis(2024)10.1016/j.jcf.2024.02.003

N/A

0.457DataRank · unranked

20 citations

Timothy E. Corcoran, Joseph M. Pilewski, Beth L. Laube, Peter J. Mogayzel, Agathe Ceppe +8 more

Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor

Annals of the American Thoracic Society(2025)10.1513/annalsats.202507-817oc

N/A

0.396DataRank · unranked

8 citations

T. Spencer Poore, Brandie D. Wagner, Jing Xie, Sonya L. Heltshe, Mary Cross +65 more

106 Impact of discontinuing hypertonic saline and dornase alfa in people with cystic fibrosis established on elexacaftor-tezacaftor-ivacaftor: A SIMPLIFY ancillary study

Journal of Cystic Fibrosis(2023)10.1016/s1569-1993(23)01041-x

N/A

0DataRank · unranked

1 citations

Alex H. Gifford, Margaret Kloster, Richard Russell, Andrew T. Braun, Ronald L. Gibson +9 more

579 Lipid concentrations after 12 to 18 months of clinically prescribed elexacaftor tezacaftor ivacaftor—PROMISE substudy

Journal of Cystic Fibrosis(2023)10.1016/s1569-1993(23)01501-1

N/A

0DataRank · unranked

0 citations

Michael S. Stalvey, David P. Nichols, Steven M. Rowe, Sarah Jane Schwarzenberg, Ben Freedman +3 more

528 Alterations in the fecal microbiota of patients with advanced cystic fibrosis–associated liver disease after 6 months of elexacaftortezacaftor-ivacaftor

Journal of Cystic Fibrosis(2023)10.1016/s1569-1993(23)01451-0

N/A

0DataRank · unranked

0 citations

Cassie F. Pope, H. Hayden, C. Miller, S. Salipante, Steven M. Rowe +6 more

Alterations in the fecal microbiota in patients with advanced cystic fibrosis liver disease after 6 months of elexacaftor/tezacaftor/ivacaftor

Journal of Cystic Fibrosis(2024)10.1016/j.jcf.2024.02.015

N/A

0DataRank · unranked

12 citations

Christopher E. Pope, Hillary S. Hayden, Carson J. Miller, Stephen J. Salipante, Steven M. Rowe +6 more

Impact of Discontinuing Both Hypertonic Saline and Dornase Alfa after Elexacaftor-Tezacaftor-Ivacaftor in Cystic Fibrosis

Annals of the American Thoracic Society(2024)10.1513/annalsats.202404-366oc

N/A

0DataRank · unranked

10 citations

Alex H. Gifford, Margaret Kloster, Renee Russell, Andrew T. Braun, Ronald L. Gibson +11 more

Longitudinal improvements in clinical and functional outcomes following initiation of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis

Heliyon(2024)10.1016/j.heliyon.2024.e29188

N/A

0DataRank · unranked

2 citations

Hui Min Leung, Amilcar Barrios, J S H Wade, Heather Hathorne, David P. Nichols +4 more

Fecal microbiota changes in people with cystic fibrosis after 6 months of elexacaftor/tezacaftor/ivacaftor: Findings from the promise study

Journal of Cystic Fibrosis(2025)10.1016/j.jcf.2025.05.006

N/A

0DataRank · unranked

14 citations

Hillary S. Hayden, Adrian J. Verster, Christopher E. Pope, Carson J. Miller, Kelsi Penewit +9 more

Optimized Monothiol Thioredoxin Derivative (ORP100S) Protects In Vitro and In Vivo from Radiation and Chemotoxicity Without Promoting Tumor Proliferation

Advanced Science(2025)10.1002/advs.202504426

N/A

0DataRank · unranked

0 citations

Xiaobei Wang, Parker Mathews, Shaima Jabbar, Min Zhang, Haim Moskowitz +14 more

Long-term azithromycin use is not associated with QT prolongation in children with cystic fibrosis

Journal of Cystic Fibrosis(2020)10.1016/j.jcf.2020.11.005

N/A

0DataRank · unranked

7 citations

Jack C. Salerno, Jason F. Deen, Margaret Kloster, Nicole Mayer-Hamblett, Bonnie W. Ramsey +2 more

SERCA2 Regulates Non-CF and CF Airway Epithelial Cell Response to Ozone

UNC Libraries(2020)10.17615/mzhz-bt48

N/A

0DataRank · unranked

0 citations

Carl W. White, Raymond C. Rancourt, Aftab Ahmad, Shama Ahmad, Scott H. Randell +2 more

Neutrophil Extracellular Trap (NET)-Mediated Killing of Pseudomonas aeruginosa: Evidence of Acquired Resistance within the CF Airway, Independent of CFTR

UNC Libraries(2020)10.17615/rk4n-6503

N/A

0DataRank · unranked

0 citations

Kenneth C. Malcolm, Michael L. Vasil, Jennifer L. Taylor‐Cousar, Katie R. Poch, Jerry A. Nick +8 more

Association Between Number of Intravenous Antipseudomonal Antibiotics and Clinical Outcomes of Pediatric Cystic Fibrosis Pulmonary Exacerbations

Clinical Infectious Diseases(2021)10.1093/cid/ciab525

N/A

0DataRank · unranked

14 citations

Anna Faino, Frankline Onchiri, Lucas R. Hoffman, Matthew P. Kronman, David P. Nichols +3 more

Drugs, Drugs, Drugs: Current Treatment Paradigms in Cystic Fibrosis Airway Infections

Journal of the Pediatric Infectious Diseases Society(2022)10.1093/jpids/piac061

N/A

0DataRank · unranked

11 citations

David P. Nichols, Christopher H. Goss, Ranjani Somayaji, Jonathan D. Cogen

Novel Applications of Biomarkers and Personalized Medicine in Cystic Fibrosis

Clinics in Chest Medicine(2022)10.1016/j.ccm.2022.06.005

N/A

0DataRank · unranked

5 citations

David P. Nichols, John J. Brewington, Jennifer S. Guimbellot

The impact of elexacaftor/tezacaftor/ivacaftor on fat-soluble vitamin levels in people with cystic fibrosis

Journal of Cystic Fibrosis(2023)10.1016/j.jcf.2023.08.002

N/A

0DataRank · unranked

30 citations

Anna Faino, Gracia Bridges, Lauren Bartlett, Jonathan D. Cogen, Nicole Green +4 more